RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $102 | $291 | $478 | $707 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $22 | $16 | $21 | $19 |
| Total Curr. Assets | $123 | $307 | $499 | $726 |
| Property Plant & Equip (Net) | $58 | $70 | $76 | $4 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $6 | $6 | $6 | $6 |
| Total NC Assets | $64 | $75 | $82 | $10 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $187 | $382 | $581 | $736 |
| Liabilities | – | – | – | – |
| Payables | $39 | $64 | $37 | $45 |
| Short-Term Debt | $1,215 | $87 | $66 | $8 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $77 | $77 | $77 | $77 |
| Other Curr. Liab. | $469 | $326 | $263 | $298 |
| Total Curr. Liab. | $1,800 | $554 | $476 | $433 |
| LT Debt | $280 | $1,403 | $1,355 | $1,254 |
| Deferred Rev, NC | $1,852 | $1,871 | $1,890 | $1,909 |
| Deferred Tax Liab, NC | $0 | -$1,373 | $0 | $0 |
| Other NC Liab. | $0 | $1,373 | $0 | $0 |
| Total NC Liab. | $2,132 | $3,274 | $3,246 | $3,163 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $64 | $74 | $75 | $4 |
| Total Liabilities | $3,931 | $3,828 | $3,722 | $3,596 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $144 | $144 | $144 | $144 |
| Retained Earnings | -$112,602 | -$112,217 | -$111,826 | -$111,460 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $108,714 | $108,628 | $108,542 | $108,455 |
| Total Equity | -$3,744 | -$3,445 | -$3,141 | -$2,861 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $187 | $382 | $581 | $736 |
| Net Debt | $1,393 | $1,199 | $943 | $556 |